![]() | ![]() |
Formats:
|
||||||||||||||||||||
Copyright © 2005, Genetics Society of America Bonus, a Drosophila TIF1 Homolog, Is a Chromatin-Associated Protein That Acts as a Modifier of Position-Effect Variegation *Department of Molecular and Human Genetics, Howard Hughes Medical Institute, Baylor College of Medicine, Houston, Texas 77030 †Department of Zoology, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada ‡Department of Biology, Davidson College, Davidson, North Carolina 28036 §Department of Biological Sciences, Stanford University, Stanford, California 94305 1Present address: Department of Human Genetics, Howard Hughes Medical Institute, University of Utah, Salt Lake City, UT 84112. 2Corresponding author: Howard Hughes Medical Institute, Baylor College of Medicine, 1 Baylor Plaza T628, Houston, TX 77030. E-mail: hbellen/at/bcm.tmc.edu Communicating editor: K. G. Golic Received October 1, 2004; Accepted November 10, 2004. This article has been cited by other articles in PMC.Abstract Bonus, a Drosophila TIF1 homolog, is a nuclear receptor cofactor required for viability, molting, and numerous morphological events. Here we establish a role for Bonus in the modulation of chromatin structure. We show that weak loss-of-function alleles of bonus have a more deleterious effect on males than on females. This male-enhanced lethality is not due to a defect in dosage compensation or somatic sex differentiation, but to the presence of the Y chromosome. Additionally, we show that bonus acts as both an enhancer and a suppressor of position-effect variegation. By immunostaining, we demonstrate that Bonus is associated with both interphase and prophase chromosomes and through chromatin immunoprecipitation show that two of these sites correspond to the histone gene cluster and the Stellate locus. POSITIONAL information and domains of higher-order chromatin modulate gene expression in eukaryotes. Chromatin can be divided into two types of domains: euchromatic (noncondensed) and heterochromatic (condensed). Euchromatin, which is generally more accessible to the transcriptional machinery and therefore transcriptionally permissive, is composed of mostly single-copy DNA sequences. In contrast, heterochromatin is generally more inaccessible to DNA-binding transcription factors and is predominantly transcriptionally silent (Henikoff 2000; Grewal and Moazed 2003). In Drosophila, large domains of heterochromatin are present at centromeres and telomeres, while smaller domains of heterochromatin are present throughout the genome (Grewal and Elgin 2002). Despite the important role of heterochromatin in chromosomal architecture and gene expression, many of the components underlying its formation and propagation have yet to be identified and characterized. Much of the information regarding heterochromatin has come from studying its ability to repress transcription in Drosophila (Weiler and Wakimoto 1995). Transcriptional repression occurs when a euchromatic gene is placed near or in regions of heterochromatin through chromosomal rearrangement or transposable-element-mediated insertion. In this new environment, a subset of cells assumes a repressed transcriptional state that is propagated through multiple cell divisions. This mosaic gene expression is termed position-effect variegation (PEV) and is believed to result from the spreading of condensed, higher-order structured heterochromatin into neighboring euchromatin (Demerec and Slizynska 1937; Grigliatti 1992). In Drosophila, genetic screens have identified mutations that either enhance [enhancers of variegation (E(var))] or suppress [suppressors of variegation (Su(var))] the effect of PEV (Reuter and Wolff 1981; Sinclair et al. 1989). E(var) proteins are believed to participate in the formation of active chromatin domains, while Su(var) proteins participate in the formation of repressed chromatin domains. Several of these genes have been cloned and analyzed. Their protein products encode nonhistone components of heterochromatin or proteins that regulate its assembly. The ability of these modifying proteins to suppress or enhance PEV often depends on their dosage and has led to the hypothesis that heterochromatin assembly is regulated by the concentration of available components (Locke et al. 1988; Schotta et al. 2003). One PEV modifier gene, Su(var)2-5, encodes the heterochromatin-associated protein 1 (HP1; Eissenberg et al. 1990). Su(var)2-5 suppresses PEV when deleted and enhances PEV when duplicated (Eissenberg et al. 1990, 1992). Molecular studies have shown that HP1 is an essential component of heterochromatin and is required for transcriptional regulation, chromosome segregation, and structural integrity of the interphase nucleus (Kellum 2003). Interestingly, the ability of HP1 to efficiently bind and increase heterochromatin assembly depends upon its ability to be phosphorylated (Zhao et al. 2001). Moreover, Piacentini et al. (2003) have recently demonstrated that HP1 is unexpectedly associated with transcriptionally active regions of euchromatin. They showed that HP1 recruited to heat-shock and ecdysone-activated puffs plays a positive regulatory role in the transcription of genes located at these sites as compared to its more studied role in silencing. Several proteins that either interact with or modify HP1 have been identified (Grewal and Moazed 2003). One of these families of proteins is the TIF1 family. The TIF1 family of proteins, TIF1α (Le Douarin et al. 1995), TIF1β [also called KAP-1 (Friedman et al. 1996) or KRIP-1 (Kim et al. 1996)], and TIF1γ (Venturini et al. 1999), are all structurally and functionally similar. All family members have an N-terminal RING finger, B boxes, and a coiled-coil domain (RBCC) followed by a C-terminal PHD finger and a bromodomain. They also have intrinsic kinase activity and repress transcription when tethered to a promoter (Fraser et al. 1998; Nielsen et al. 1999; Venturini et al. 1999). In addition, TIF1α and TIF1β recruit histone deacetylases (HDAC) to repress transcription (Nielsen et al. 1999). Interestingly, TIF1α and TIF1β have been shown to interact with and phosphorylate vertebrate homologs of HP1 (Le Douarin et al. 1998; Nielsen et al. 1999; Ryan et al. 1999). Thus, the ability of TIF1 family members to recruit HDAC and phosphorylate vertebrate homologs of HP1 suggests that they may have essential roles in the regulation of chromatin. Unfortunately, the in vivo relevance of these biochemical interactions has not been established due to the early lethality associated with mutations in mouse TIF1β and the lack of mutation in vertebrate TIF1α and -γ (Cammas et al. 2000). Previously, we reported the isolation of the Drosophila homolog of the TIF1 family, Bonus (Bon), and established Drosophila as a valuable model organism for studying the in vivo function of the TIF1 family (Beckstead et al. 2001). Bon is the only Drosophila homolog of the TIF1 family and is expressed throughout development. Mutational analysis revealed that bon is required for numerous events in metamorphosis, including leg elongation, bristle development, and salivary gland cell death. Bon was shown to interact biochemically with several Drosophila nuclear receptors. Specifically, it was demonstrated, both genetically and biochemically, that Bon is able to bind to and inhibit the transcriptional activity of βFTZ-F1, a component of the ecdysone transcriptional cascade, providing the first in vivo evidence for a role of a TIF1 homolog in nuclear receptor signaling. During our phenotypic characterization of different bon alleles, we observed that partial loss-of-function alleles had a more deleterious effect on males than on females. Here we expand on this observation and report a new allele of bon that is male specific lethal and female viable. We show that the male lethality associated with bon alleles is not due to defects in dosage compensation or sex determination pathways, but rather to the presence of the Y chromosome. We also show that an increase in X-heterochromatin results in a decrease in the viability of bon mutant animals. In addition, loss-of-function bon alleles dominantly suppress the PEV of the y+ gene and dominantly enhance the PEV of the w+ gene, suggesting that Bon plays an important positive and negative regulatory role in transcription. Finally, chromatin immunoprecipitation assays indicate that Bon is associated with the histone cluster and Stellate locus, two loci that display properties of β-heterochromatin. MATERIALS AND METHODS Immunohistochemistry and microscopy: Guinea pig anti-Bon (Beckstead et al. 2001) was used as a primary antibody and fluorescent conjugated goat anti-guinea pig antibody (Molecular Probes, Eugene, OR) was used as the secondary antibody. TOTO-3 iodide (Molecular Probes) was used to visualize DNA. Prepupal brains of 0 hr were dissected in a 0.7% NaCl solution followed by a 10-min incubation in 0.5% sodium citrate solution. Brains were fixed in 45% acetic acid containing 2% formaldehyde for 3 min, squashed between a slide and coverslip, and frozen in liquid nitrogen. After removal of the coverslip, the slide was incubated in 1% Triton X-100 for 10 min prior to staining (Pimpinelli et al. 2000). Alternatively, the slide was incubated in 45% acetic acid for 3 min, squashed, and frozen. The coverslip was removed, and the sample incubated in 1% Triton X-100 for 10 min and then fixed in 2% formaldehyde for 3 min prior to staining. Brain images were captured using a Bio-Rad (Richmond, CA) MRC 600 laser scanning confocal microscope. Animals were photographed using a Zeiss Stemi SV8 and Hamamatsu digital camera. See Table 1 for Drosophila stocks.
Chromatin immunoprecipitation: Formaldehyde crosslinked chromatin fragments were prepared by sonication of 8- to 16-hr-old embryos (Orlando et al. 1997). The crosslinked nucleoprotein complexes were isolated by immunoprecipitation using an antibody against Bon (Beckstead et al. 2001) and dimethyl-lysine 9 histone H3 peptide. The DNA-protein complexes were reverse crosslinked for 5 hr at 65°. DNA was purified by phenol-chloroform extraction and recovered by ethanol precipitation. Precipitated DNA was analyzed by non-real-time PCR using primers specific to regions of the his unit (accession no. X14215; Matsuo and Yamazaki 1989) and the Stellate cluster (accession no. X15899.1; Livak 1990). The PCR conditions used for amplification were denaturation at 92° for 50 sec, annealing at 57° for 1 min, and extension at 72° for 2 min 30 sec. This cycle was repeated 25 times for all primer pairs except P6 and P8, which required 28 cycles for efficient detection of the products. To verify specific enrichment of DNA fragments by the antibodies used, we performed several controls. First, we used an antibody that recognizes the T7-Tag. Drosophila does not contain any proteins with this sequence and therefore we expected no pull-down with the T7 antibody, which proved to be the case. Second, we performed a mock immunoprecipitation reaction using only blocked protein A sepharose beads. This control determines the level of nonspecific DNA interactions with the beads and is essentially negligible in our experiments. Third, to rule out the possibility that any observed enrichment of histone sequences was not a consequence of the multiple gene copies present, we examined another reiterated set of genes located elsewhere in the genome. These were the 5S rRNA cluster (accession no. X06938) and ubiquitin protein gene DROUBIA (accession no. M22428). Sequences corresponding to these loci were not enriched when chromatin was immunoprecipitated with the Bon antibody or the control antibody (Figure 6D
RESULTS Loss-of-function mutations of bonus are male specific lethal: Phenotypic analysis of bon loss-of-function mutations suggested that males are more affected by the loss of bon than females (Beckstead et al. 2001). We have identified a mutation, P{lacW}043420 (Deak et al. 1997), that caused male-specific lethality and mapped ~100 nucleotides into the 5′-UTR of the bon gene. As shown in Figure 1A
To better characterize the lethal phase of each sex in different bon mutant backgrounds, we examined the percentage of homozygous males and females that die during the first instar larval stage for bon434 and bon241; partial loss-of-function alleles; and bon21B, a null allele (Figure 1B Male lethality is not due to defects in the sex determination and dosage compensation pathways: In Drosophila development, Sex lethal (Sxl) is upregulated in females and remains silent in males (Cline 1993). Sxl directs sexual development in females by controlling the female-specific splicing of the transformer (tra) gene (Lucchesi 1978; Boggs et al. 1987). Expression of Sxl in males is lethal, as it will lead to a lack of dosage compensation through its regulation of splicing and translation of male-specific-lethal 2 (msl2; Bashaw and Baker 1997; Kelley et al. 1997). The sex-specific requirement of Sxl is seen in the loss-of-function (SxlF1) and the gain-of-function (SxlM1) Sxl mutations. Loss of Sxl associated with SxlF1 results in female-specific lethality, while ectopic expression of Sxl in the gain-of-function mutation SxlM1 results in male-specific lethality (Muller and Zimmering 1960; Skripsky and Lucchesi 1982). To determine whether the bon male-specific lethality is due to aberrant expression of the Sxl gene in bon males, we created homozygous bon434 males that lacked Sxl gene function by crossing SxlF1/FM7; bon434/TM6 females to SxlF1/Y; bon434/TM6B males. As seen in Figure 2A
We next tested whether defects in X chromosome dosage compensation could be the basis of the bon434 male-specific lethality. In Drosophila males, dosage compensation increases the transcriptional rate of genes on the X chromosome to compensate for the presence of only one X chromosome. This process is mediated by five msl genes: maleless (mle), the male-specific-lethal genes (msl1, msl2, msl3), and males absent on the first (mof; Cline and Meyer 1996). Protein products of the msl genes form a complex with the noncoding RNA products of the roX1 and roX2 genes to mediate dosage compensation by regulating the chromatin structure on the male X chromosome (Franke et al. 1996). To determine whether msl genes were properly expressed in the bon male embryos, we stained embryos with anti-MSL1 antibodies. As seen in Figure 2, B and C To test whether reduced levels of Bon impede the mechanism of dosage compensation, we expressed a MSL2 (MCdelta3′-10) in bon females (Bashaw and Baker 1997). Expression of MSL2 in females results in the activation of the dosage compensation pathway. Some cells that express MSL2 upregulate dosage compensation, giving rise to females with a 3X2A phenotype. As shown in Figure 2D To determine whether the somatic sex of the animals plays a role in bon-induced male lethality, we tested whether 2X female animals that are somatically male are lethal when homozygous for bon434. We generated homozygous bon434 females that are mutant for the tra-2 gene and hence develop somatically as males (Belote and Baker 1987). As seen in Figure 2E Male lethality is due to the presence of the Y chromosome: Because the bon male lethality is not due to defects in sex determination pathways, we tested whether the presence or absence of the Y chromosome influences the phase of lethality. In Drosophila, the Y chromosome, which accounts for ~12% of the male genome, is made up almost entirely of heterochromatin and functions as a Su(var) (Pimpinelli et al. 1978; Dimitri and Pisano 1989). The Y chromosome itself is not necessary for male viability, but contains genes that are required for male fertility, as well as the bobbed (bb) locus, which encodes rRNA genes (Stern 1927; Brosseau 1960; Kennison and Ripoll 1981; Carvalho et al. 2001). To test whether male lethality of bon434 is caused by the Y chromosome, we crossed bon434/TM6 males that contained a compound X-Y chromosome (C(1:Y) y1 BS) to bon434/TM6 females to produce males that lacked the Y chromosome (XO) and females that contain the Y chromosome (XXY; Figure 3A
The bon Y-conditional lethality suggested that the viability of bon434/bon434 animals may depend on the levels of heterochromatin present in the genome. To test this hypothesis, we generated female flies that contained an additional copy of heterochromatic DNA that is associated with the X chromosome (20A-h26) (Dobzhansky 1932). The presence of this additional heterochromatin resulted in a 60% decrease in viability of bon434/bon434 female adults as compared to those that lack the additional X heterochromatic DNA (Figure 3B bonus acts as both an Enhancer and a Suppressor of position-effect variegation: Because of the interaction of bon with heterochromatin, we wished to determine if bon affects heterochromatin formation or spreading. We therefore tested the ability of different loss-of-function bon mutations to modify the expression pattern of euchromatic genes that were inserted on the Y chromosome. Two SUPor-P-element lines, which map to the Y chromosome, were obtained (Roseman et al. 1995). Data for y1 P{y+mDint2 wBR.E.BR=SUPor-P}25-4-3 and y1 P{y+mDint2 wBR.E.BR=SUPor-P}222-1 were similar, and only data for y1 P{y+mDint2 wBR.E.BR=SUPor-P}25-4-3 are shown. SUPor-P elements (Figure 4A
The observation that the wild-type allele of bon is simultaneously an E(var) and Su(var) may be due to the properties of the SUPor-P element. The Su(Hw)-binding sites flanking the w+ gene may buffer or alter the effect of the loss of Bon. We therefore determined if removal of a copy of bon could affect the variegation of a w+ gene that is in close proximity heterochromatin at the base of the X chromosome, using the white-mottled (l(1)wM4H) chromosome (Reuter and Wolff 1981). As shown in Figure 4H Bonus is associated with both interphase and prometaphase chromosomes: Because of the genetic interaction between Bon and heterochromatin and the observations that Bon mutants can act as both a Su(var) and an E(var), we were interested in determining whether Bon is localized to regions of heterochromatin or euchromatin in interphase and prometaphase cells. We therefore stained 0-hr prepupal brains with a Bon antibody (Beckstead et al. 2001). The specificity of the Bon antibody was previously demonstrated by the almost complete lack of staining seen in the bon21B/bon21B mutant embryos and the significant decrease in protein levels as determined by Western analysis of bon487/bon21B prepupae (4 hr old) as compared to the bon21B/+ control. This time point and tissue were chosen due to the high levels of Bon that are detected during this stage and the ease of viewing brain cells that undergo numerous rounds of cell division. As shown in Figure 5A
Bonus is associated with many loci, including the histone cluster and the Stellate locus: Previous immunostaining of salivary gland polytene chromosomes and staining presented here of larval mitotic chromosomes and interphase nuclei with the Bon antibody reveals that the Bon protein is present at numerous sites (Beckstead et al. 2001). Further examination of the polytene staining suggested that the histone cluster (HIS-C) located at the 39D-E region of chromosome 2 is a site of Bon localization (data not shown). To confirm this observation and to gain an insight into the Bon distribution at the histone cluster, we performed a ChIP analysis using the Bon antibody on chromatin prepared from 8- to 16-hr embryos. HIS-C is a large multicopy histone gene complex and comprises ~0.5 Mb of DNA containing 110 copies of the five histone genes (his unit; Samal et al. 1981). It is also the site of localization of Su(var)3-9 (Ner et al. 2002) and HP1 (van Steensel et al. 2001), two proteins involved in organizing chromatin structure. Chromatin immunoprecipitations were performed using the Bon antibody, the anti-diMe-Lys9 H3 antibody (Belote and Baker 1987), and a control anti-T7 antibody. Any enrichment of DNA fragments corresponding to those of the HIS-C was detected by PCR. Seven pairs of oligonucleotide primers that hybridize within the 5-kb his units were used to detect DNA fragments pulled down by the antibodies. Two primer pairs amplified coding regions of HIS2B and HIS4 (Figure 6A Next, we examined the Stellate locus on the X chromosome (12E1-2). We examined this region to ask if other reiterated euchromatic loci are also sites for Bon. The Stellate complex is significantly smaller than HIS-C (~30 kb in size) and comprises ~20 copies of the Stellate gene. We examined for enrichment of Stellate sequences that are unique only to the X chromosome cluster. Immunoprecipitation using the Bon antibody was performed on chromatin prepared from wild-type flies and bon434/TM3 flies. Figure 6C DISCUSSION These studies define a new role for Bon in the organization of chromatin and provide new insights into its possible regulation of transcription. We show that the enhanced male lethality in bon partial loss-of-function alleles is due to the presence of the Y chromosome. We further show an interaction between bon and X-heterochromatin, demonstrating a broader interaction with heterochromatic sequences, and thus uncover a new function for this transcription cofactor. Interestingly, depending on the gene, bon can function as either a Su(var) or an E(var). Localization of Bon along the entire pro-metaphase chromosome suggests that Bon may play a more general role in chromatin organization near many genes. Using ChIP data, we show that Bon is associated with chromatin. Specifically, we demonstrate that Bon is at the HIS-C and Stellate loci. Clearly, the absence of Bon at heterochromatin, which is highly enriched in repetitive DNA sequences, along with its association with two reiterated euchromatic loci that are highly expressed, suggests that the function of Bon is not simply in the packaging of repeat sequences. One possibility is that Bon has a role in chromatin organization of transcriptionally competent loci such as HIS-C and Stellate, as well as the numerous euchromatic loci where Bon is present. Additionally, our data provide the first in vivo example of the requirement of a TIF1 family member in the regulation of chromatin. The Y chromosome may act as a sink for Bonus: Two other Su(var) genes, Su(var)2-1 and Su(var)3-3, show a similar lethal interaction with the Y chromosome as bon (Reuter et al. 1982; Dorn et al. 1986). Interestingly, through Y chromosome deletions, it was demonstrated that the strength of the genetic interaction between the Y chromosome and Su(var)2-1 was related to the amount of Y heterochromatin and not to a discrete Y region (Dimitri and Pisano 1989). Our data, demonstrating a genetic interaction between bon and X-heterochromatin, suggest that the bon Y-conditional lethality, like Su(var)2-1, is most likely due to the heterochromatic nature of the Y chromosome and not to a specific Y region. On the basis of our knowledge of Bon function, we propose the following model to account for the dramatic effects that the presence/absence of the Y chromosome (and other heterochromatin) has on the viability of flies carrying weak alleles of bon. In wild-type animals, Bon is not limiting and occupies both heterochromatic and euchromatic sites, playing an essential role in gene regulation. As the amount of functional Bon activity becomes limiting in bon mutant animals, some of the Bon protein is sequestered to heterochromatic sites, thus making a fraction of Bon unavailable to euchromatic sites where it is essential for viability. The removal of the Y chromosome or other chromatin allows more Bon to be available for those sites where it plays essential roles, hence suppressing the lethality associated with the partial loss of function of bon. In other words, the presence of the Y chromosome makes a weak bon loss-of-function allele in the male act as a strong loss-of-function or null allele. Thus, the stage of lethality for bon partial loss-of-function males is similar to both Bon null females and male animals. This model is supported also by the localization of Bon to the Y chromosome, as well as by the genetic interaction observed between Bon and X-heterochromatin. Bonus participates in the regulation of chromatin: To determine if Bon plays a role in the regulation of chromatin packaging, we assayed the effect of bon mutations on variegation of the white and yellow genes found in several SUPor-P elements located on the Y chromosome. Interestingly, loss of bon enhanced variegation of the white gene and suppressed variegation of the yellow gene in the same animal. We also observed that bon mutations act as an E(var) in the white-mottled (l(1)wM4H) background and a Su(var) in a γ878 background. These results indicate that Bon plays a role in the regulation of heterochromatin, but also suggest that the role of Bon is gene specific. Finally, we note that HP1 and TIF1(Bonus) share several features. First, both Bon and HP1 can function as Su(var)'s and have been shown to play both positive and negative roles in the regulation of transcription (Eissenberg et al. 1990; Beckstead et al. 2001; Piacentini et al. 2003). Second, both Bon and HP1 participate in the transcriptional response to ecdysone (Beckstead et al. 2001; Piacentini et al. 2003). Third, TIF1 members have been shown to interact with and phosphorylate HP1 (Le Douarin et al. 1998; Nielsen et al. 1999; Ryan et al. 1999). Fourth, ChIP assays indicate that Bonus and HP1 are associated with the same DNA fragments in the histone cluster (van Steensel et al. 2001) and Stellate loci. The in vivo relationship between Bonus and HP1 should therefore be explored. Acknowledgments R.B.B. thanks Carl Thummel for allowing him to finish this work in his laboratory. We thank the Bloomington Stock Center for numerous fly strains and Karen Schulze for comments on the manuscript. R.B.B. was supported by a National Aeronautics and Space Administration grant and is currently a Howard Hughes Medical Institute (HHMI) associate, B.S.B. is supported by the National Institute of General Medical Sciences, T.A.G. and S.S.R. are supported by National Science and Engineering Council of Canada operating grant A3005 and National Cancer Institute of Canada research grant no. 013378, and H.J.B. is an Investigator of the HHMI. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||
Science. 2003 Aug 8; 301(5634):798-802.
[Science. 2003]Curr Opin Genet Dev. 2002 Apr; 12(2):178-87.
[Curr Opin Genet Dev. 2002]Annu Rev Genet. 1995; 29():577-605.
[Annu Rev Genet. 1995]Mol Gen Genet. 1981; 182(3):516-9.
[Mol Gen Genet. 1981]Mol Gen Genet. 1989 Apr; 216(2-3):328-33.
[Mol Gen Genet. 1989]Genetics. 1988 Sep; 120(1):181-98.
[Genetics. 1988]Semin Cell Dev Biol. 2003 Feb; 14(1):67-75.
[Semin Cell Dev Biol. 2003]Proc Natl Acad Sci U S A. 1990 Dec; 87(24):9923-7.
[Proc Natl Acad Sci U S A. 1990]Genetics. 1992 Jun; 131(2):345-52.
[Genetics. 1992]Curr Top Microbiol Immunol. 2003; 274():53-77.
[Curr Top Microbiol Immunol. 2003]J Biol Chem. 2001 Mar 23; 276(12):9512-8.
[J Biol Chem. 2001]J Cell Biol. 2003 May 26; 161(4):707-14.
[J Cell Biol. 2003]Science. 2003 Aug 8; 301(5634):798-802.
[Science. 2003]EMBO J. 1995 May 1; 14(9):2020-33.
[EMBO J. 1995]Genes Dev. 1996 Aug 15; 10(16):2067-78.
[Genes Dev. 1996]Proc Natl Acad Sci U S A. 1996 Dec 24; 93(26):15299-304.
[Proc Natl Acad Sci U S A. 1996]Oncogene. 1999 Feb 4; 18(5):1209-17.
[Oncogene. 1999]Mol Cell. 2001 Apr; 7(4):753-65.
[Mol Cell. 2001]Mol Cell. 2001 Apr; 7(4):753-65.
[Mol Cell. 2001]Methods. 1997 Feb; 11(2):205-14.
[Methods. 1997]Mol Cell. 2001 Apr; 7(4):753-65.
[Mol Cell. 2001]Nucleic Acids Res. 1989 Jan 11; 17(1):225-38.
[Nucleic Acids Res. 1989]Genetics. 1990 Feb; 124(2):303-16.
[Genetics. 1990]Genetics. 2002 Dec; 162(4):1763-74.
[Genetics. 2002]Mol Cell. 2001 Apr; 7(4):753-65.
[Mol Cell. 2001]Genetics. 1997 Dec; 147(4):1697-722.
[Genetics. 1997]Mol Cell. 2001 Apr; 7(4):753-65.
[Mol Cell. 2001]Trends Genet. 1993 Nov; 9(11):385-90.
[Trends Genet. 1993]Science. 1978 Nov 17; 202(4369):711-6.
[Science. 1978]Cell. 1987 Aug 28; 50(5):739-47.
[Cell. 1987]Cell. 1997 May 30; 89(5):789-98.
[Cell. 1997]Nature. 1997 May 8; 387(6629):195-9.
[Nature. 1997]Annu Rev Genet. 1996; 30():637-702.
[Annu Rev Genet. 1996]Development. 1996 Sep; 122(9):2751-60.
[Development. 1996]Cell. 1997 May 30; 89(5):789-98.
[Cell. 1997]Proc Natl Acad Sci U S A. 1987 Nov; 84(22):8026-30.
[Proc Natl Acad Sci U S A. 1987]Chromosoma. 1978 May 16; 66(4):389-95.
[Chromosoma. 1978]Genetics. 1989 Aug; 122(4):793-800.
[Genetics. 1989]Genetics. 1981 May; 98(1):91-103.
[Genetics. 1981]Proc Natl Acad Sci U S A. 2001 Nov 6; 98(23):13225-30.
[Proc Natl Acad Sci U S A. 2001]Genetics. 1995 Nov; 141(3):1061-74.
[Genetics. 1995]EMBO J. 1993 Feb; 12(2):435-42.
[EMBO J. 1993]Mol Cell. 2001 Apr; 7(4):753-65.
[Mol Cell. 2001]Mol Gen Genet. 1981; 182(3):516-9.
[Mol Gen Genet. 1981]Genetics. 1995 Sep; 141(1):283-303.
[Genetics. 1995]Mol Cell. 2001 Apr; 7(4):753-65.
[Mol Cell. 2001]Mol Cell. 2001 Apr; 7(4):753-65.
[Mol Cell. 2001]Cell. 1981 Feb; 23(2):401-9.
[Cell. 1981]Genetics. 2002 Dec; 162(4):1763-74.
[Genetics. 2002]Nat Genet. 2001 Mar; 27(3):304-8.
[Nat Genet. 2001]Proc Natl Acad Sci U S A. 1987 Nov; 84(22):8026-30.
[Proc Natl Acad Sci U S A. 1987]Mol Gen Genet. 1982; 188(3):480-5.
[Mol Gen Genet. 1982]Genetics. 1989 Aug; 122(4):793-800.
[Genetics. 1989]Proc Natl Acad Sci U S A. 1990 Dec; 87(24):9923-7.
[Proc Natl Acad Sci U S A. 1990]Mol Cell. 2001 Apr; 7(4):753-65.
[Mol Cell. 2001]J Cell Biol. 2003 May 26; 161(4):707-14.
[J Cell Biol. 2003]J Steroid Biochem Mol Biol. 1998 Apr; 65(1-6):43-50.
[J Steroid Biochem Mol Biol. 1998]EMBO J. 1999 Nov 15; 18(22):6385-95.
[EMBO J. 1999]Genetics. 1995 Nov; 141(3):1061-74.
[Genetics. 1995]Cold Spring Harb Symp Quant Biol. 1978; 42 Pt 2():1047-51.
[Cold Spring Harb Symp Quant Biol. 1978]Cell. 1981 Feb; 23(2):401-9.
[Cell. 1981]